Calendar

Week of Apr 20, 2026

Apr 25, 2026constraining patent expiry europe108d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Europe))SL-901

Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

full page →SL-901 →source: globaldata

Apr 25, 2026patent expiry108d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

full page →SL-901 →source: globaldata

Apr 25, 2026phase 1 completion108d agoHenan Cancer Hospital — GH-2616 (Phase I Trial Completion)GH-2616

Therapy area: Oncology. Indication: Lung Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Uterine Cancer

full page →GH-2616 →source: globaldata

Apr 25, 2026phase 1 2 completion108d agoGeneral Hospital of the People's Liberation Army — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Nodal Marginal Zone B-Cell Lymphoma, Non-Hodgkin Lymphoma, Primary Mediastinal B-Cell Lymphoma, Splenic Marginal Zone B-Cell Lymphoma

full page →cyclophosphamide →source: globaldata

Apr 25, 2026phase 1 2 completion108d agoShanghai YaKe Biotechnology Co Ltd — CD7 CAR-T Cells (Phase I/II Trial Completion)CD7 CAR-T Cells

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

full page →CD7 CAR-T Cells →source: globaldata

Apr 25, 2026phase 2 completion108d agoTianjin Medical University Cancer Institute and Hospital — fluorouracil (Phase II Trial Completion)Efudex

Therapy area: Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma)

full page →Efudex →source: globaldata

Apr 25, 2026phase 2 completion108d agoTehran University of Medical Sciences — FOLFOX [leucovorin + fluorouracil + oxaliplatin] (Phase II Trial Completion)FOLFOX [leucovorin + fluorouracil + oxaliplatin]

Therapy area: Oncology. Indication: Rectal Cancer

full page →FOLFOX [leucovorin + fluorouracil + oxaliplatin] →source: globaldata

Apr 25, 2026phase 2 completion108d agoSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)blinatumomab

Therapy area: Oncology. Indication: B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

full page →blinatumomab →source: globaldata

Apr 25, 2026phase 2 initiation108d agoAffiliated Hospital of North Sichuan Medical College — Radioactive Iodine Therapy (Phase II Trial Initiation)Radioactive Iodine Therapy

Therapy area: Oncology. Indication: Follicular Thyroid Cancer, Papillary Thyroid Cancer, Thyroid Cancer

full page →Radioactive Iodine Therapy →source: globaldata

Apr 25, 2026phase 2 initiation108d agoShanghai Henlius Biotech Inc — HLX-43 (Phase II Trial Initiation)HLX-43

Therapy area: Oncology. Indication: Breast Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

full page →HLX-43 →source: globaldata

Apr 25, 2026phase 2 initiation108d agoJazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)durvalumab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →durvalumab →source: globaldata

Apr 25, 2026phase 2 initiation108d agoNovartis AG — asciminib hydrochloride (Phase II Trial Initiation)asciminib hydrochloride

Therapy area: Oncology. Indication: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

full page →asciminib hydrochloride →source: globaldata

Week of Apr 20, 2026